Home
Search
Search Results
Previously Searched
3114 results found
Expand All
Apply All
3114 results found

Good Day BIO: A milestone for vaccines
Good Day BIO Newsletter  •  January 31, 2023
A feat for vaccines, the COVID-19 public health emergency in the U.S. will end on May 11. We look back at how we got here. Plus, the CEO of one of the world’s largest fertilizer companies warns of a food crisis, but biotech is advancing solutions. (612 words, 3 minutes, 3 seconds)
Read More

Good Day BIO: Preparing for price controls
Good Day BIO Newsletter  •  January 30, 2023
Drug pricing is expected to be a hot topic in 2023—here’s what you need to know about the outlook and the importance of messaging. Plus, a new strain of a deadly pig disease highlights the importance of advancing animal biotech like gene editing. (618 words, 3 minutes, 5 seconds)
Read More

Good Day BIO: FDA panel recommends bivalent boosters only
Good Day BIO Newsletter  •  January 27, 2023
Yesterday, an FDA panel recommended retiring the monovalent COVID vaccines and using only the newer bivalent vaccines, which target variants. And before you log off for the weekend, find out where you can meet your next industry partner and learn more about BIO’s priorities for 2023 directly from BIO's Interim CEO, Rachel King. (550 words, 2 minutes, 45 seconds)
Read More

The U.S. Bioscience Industry Fosters Innovation and Drives America’s Economy Forward
Human Health, Cost & Value of Biopharmaceuticals  •  Toolkit  •  January 27, 2023
The bioscience industry and its supporting ecosystem drive bold innovations to address unmet human needs in the U.S. and around the world, including developing new breakthrough therapies that treat deadly diseases. The collective efforts of the industry and our public and private stakeholders have met the challenges of the COVID pandemic head-on, while lessening the impacts of climate change and nourishing a growing global population. 
Read More

Good Day BIO: Bivalent boosters and biotech crops
Good Day BIO Newsletter  •  January 26, 2023
Two studies published yesterday show bivalent vaccines provide better protection against new subvariants than monovalent vaccines alone. Plus: news on China’s and Mexico’s plans for biotech crops and how biotech is supercharging cancer-fighting T cells. (654 words, 3 minutes, 16 seconds)
Read More

Good Day BIO: Europe's lessons on drug price controls
Good Day BIO Newsletter  •  January 25, 2023
The Wall Street Journal Editorial Board explains why Europe’s experience should serve as a warning to the U.S. on drug price controls—something BIO’s been saying for a long time. Plus, BIO provided recommendations to the Biden administration on implementing the biomanufacturing initiative. (631 words, 3 minutes, 9 seconds)
Read More

Good Day BIO: FDA proposes annual updated COVID boosters
Good Day BIO Newsletter  •  January 24, 2023
The FDA proposes to update COVID-19 vaccines annually, like flu shots, and U.S. officials say they’re ready to take formal action on Mexico’s corn ban. (622 words, 3 minutes, 6 seconds)
Read More

IRA Drug Negotiation: At a Glance
Human Health, Inflation Reduction Act  •  Toolkit  •  January 24, 2023
Maximum Fair Price: A manufacturer of a drug selected for negotiation will be required to offer a “maximum fair price” for the selected drug with respect to Medicare beneficiaries. Timeline: The first set of drugs will be selected for negotiation in September 2023, with the negotiation process starting a month later. The first set of negotiated prices taking effect in “initial price applicability year” 2026.
Read More

BIO Response to RFI: National Biotechnology & Biomanufacturing Initiative
Human Health  •  Letters, Testimony & Comments  •  January 23, 2023
BIO's response to the Office of Science & Technology Policy's Request for Information concerning the National Biotechnology & Biomanufacturing Initiative
Read More

Good Day BIO: Biotech is the answer
Good Day BIO Newsletter  •  January 23, 2023
Climate change and food security—and the role of biotech in addressing both—were major themes at Davos last week, with BIO members in the spotlight at the event. Plus, PBMs’ formulary exclusions are increasing in 2023, and we look at what it means for patients and policy. (594 words, 2 minutes, 58 seconds)
Read More